ICP
IART icon

Interchange Capital Partners’s Integra LifeSciences IART Stock Holding History

Interchange Capital Partners’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed – – 623
2020
Q4 		$0 Buy
+5
New +$269 ﹤0.01% 1202

Other funds holding IART

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Interchange Capital Partners's IART Position: Q1 2021 in Review

Interchange Capital Partners sold out of Integra LifeSciences (IART) in Q1 2021, closing a stake of 5 shares.

Interchange Capital Partners first reported a position in IART in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 257 funds tracked by Wall St. Rank hold IART as of Q1 2021.

  • Interchange Capital Partners reported no remaining Integra LifeSciences position as of Q1 2021 after selling out during the quarter.
  • Interchange Capital Partners sold 5 Integra LifeSciences shares in Q1 2021.
  • Interchange Capital Partners first reported a position in Integra LifeSciences in Q4 2020 and held it in 1 quarter.
  • Interchange Capital Partners's Integra LifeSciences position peaked at $0 in Q4 2020.
  • 257 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2021.

Based on Interchange Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.